Search details
1.
Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells.
BMC Cancer
; 17(1): 630, 2017 Sep 06.
Article
in English
| MEDLINE | ID: mdl-28877686
2.
Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia.
Mol Cancer
; 13: 116, 2014 May 21.
Article
in English
| MEDLINE | ID: mdl-24885082
3.
Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment.
Am J Hematol
; 87(4): 368-76, 2012 Apr.
Article
in English
| MEDLINE | ID: mdl-22374841
4.
Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy.
Cells
; 8(10)2019 10 10.
Article
in English
| MEDLINE | ID: mdl-31658693
5.
Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation.
Oncotarget
; 6(5): 2794-811, 2015 Feb 20.
Article
in English
| MEDLINE | ID: mdl-25605239
6.
Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents.
Clin Epigenetics
; 5(1): 12, 2013 Jul 30.
Article
in English
| MEDLINE | ID: mdl-23898968
7.
The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicinethe experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation.
Toxins (Basel)
; 5(2): 336-62, 2013 Feb 18.
Article
in English
| MEDLINE | ID: mdl-23430540
8.
The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia.
Clin Epigenetics
; 5(1): 13, 2013 Aug 01.
Article
in English
| MEDLINE | ID: mdl-23915396
9.
CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia.
Oncotarget
; 4(9): 1438-48, 2013 Sep.
Article
in English
| MEDLINE | ID: mdl-23988457
10.
The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation.
Eur Cytokine Netw
; 23(4): 140-53, 2012.
Article
in English
| MEDLINE | ID: mdl-23328436
11.
Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis.
Oncol Rep
; 25(6): 1549-56, 2011 Jun.
Article
in English
| MEDLINE | ID: mdl-21431284
12.
Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia--a report of five cases.
Hematology
; 15(5): 338-43, 2010 Oct.
Article
in English
| MEDLINE | ID: mdl-20863429
Results
1 -
12
de 12
1
Next >
>>